ArriVent BioPharma, Inc. — Investor Relations & Filings

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy involves forging strategic collaborations to in-license and advance promising drug candidates for global patient populations. Its lead development candidate is firmonertinib, a novel therapeutic for cancer. ArriVent's pipeline also includes other oncology therapeutics, such as next-generation antibody drug conjugates. The company leverages its team's extensive drug development and regulatory experience to design development strategies with clear paths to approval, aiming to address significant unmet medical needs.